Optimistic Long-Term Outlook for Rocket Pharmaceuticals Amid Promising Study Results and Undervalued Stock Potential
Analyst Eric Joseph of J.P. Morgan maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report), retaining the price target of ...
Rocket Pharmaceuticals’ RP-A501 Shows Promising Long-Term Efficacy and Safety in Danon Disease Treatment: Buy Rating Affirmed
In a report released yesterday, Michael Ulz from Morgan Stanley reiterated a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report), ...